
Truveta brand logo mark in teal on a black background, featuring stacked chevron shapes forming the Truveta symbol.
Close

Saving Lives with Data

Turning real-world data into intelligence, evidence, and better care

Answers can't wait
Let's talk today

Answers can’t wait

Let's talk today

Truveta Data

The most complete, real-time view of US healthcare

1 in 3 Americans
All care settings
Updated daily
10+ years of history

130M+

Patients and growing

Longitudinally linked:

EHR
Closed claims
Devices
Images
SDOH
Mother-child
Multiomics
Mortality
Explore Truveta Data

Truveta Intelligence

Answers in minutes, not months

Explore Truveta Intelligence
Explore Truveta Intelligence

Truveta Evidence

Confidence through rigorous analytics and expertise

Trusted research environment

Immediately access Truveta Data and execute full research studies
Dynamically refine cohorts with reusable, clinically precise definitions
Produce audit-ready evidence aligned to regulatory standards
Explore Truveta Evidence

Truveta Evidence Services

Design rigorous studies alongside experts and deliver transparent, audit-ready evidence

Extend capacity with trusted experts
Accelerate timelines from protocol to submission
Maximize value from real-world data
De-risk high-impact regulatory and post-market studies
Learn more
350+

Publications

250+

Conference presenations

150+

Citations

100+

Regulatory projects across US and global agencies

Learn more

Power every stage of care

Advance every decision with real-time intelligence and regulatory-grade evidence

Discovery

Discover new targets and train AI

Therapy adoption

Track patient access and industry trends in real time

Safety

Uncover safety signals faster from real-time data trusted by regulators

Outcomes research

Update evidence strategies in real-time across precise populations

Clinical trials

Simulate trials and identify eligible patients with unprecedented precision

Healthcare optimization

Benchmark care quality and enhance operations

Built with US health systems

Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Meet our members
Pharmaceutical
Medical device
Healthcare
Public health
Academics

Ready for the entire healthcare ecosystem

Ready for the entire healthcare ecosystem

Pharmaceutical
Medical device
Public health
Healthcare
Academics

Trusted by leading life science, public health, and healthcare organizations

Moderna
Boehringer Ingleheim
Providence
Boston Scientific
CommonSpirit
SK
Medcomp
Advocate
Northwell

Featured research

CDC study links later clinic visits to lower antihypertensive adherence

CDC study links later clinic visits to lower antihypertensive adherence

A CDC-led study published in the American Journal of Preventive Medicine used linked electronic health records and pharmacy dispensing data from Truveta to analyze 4,027,607 antihypertensive prescriptions among 936,502 US adults with hypertension. Compared with 7 am...
Estrogen-based hormone replacement therapy use is rising

Estrogen-based hormone replacement therapy use is rising

Estrogen-based hormone replacement therapy (HRT) prescribing more than doubled from 2018 to 2026. The largest increases were seen in patches and vaginal creams, with patch use more than tripling and vaginal cream use increasing more than fourfold. The rates of women...
CDC publishes national COVID-19 analysis using Truveta Data in the MMWR

CDC publishes national COVID-19 analysis using Truveta Data

Older adults remain at highest risk for COVID-19–related hospitalization. Yet a new CDC analysis suggests that effective antiviral treatments are likely underprescribed among outpatients aged 65 or older, with prescribing patterns varying alongside disease...
Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval – Truveta research report cover image.

Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval

A large proportion of early users (36.1%) of oral semaglutide (Wegovy pill) had no prior evidence of GLP-1-based medication use, suggesting rapid uptake among patients new to taking GLP-1 medications. Among patients who previously used a GLP-1-based medication, most...
CDC study links later clinic visits to lower antihypertensive adherence

CDC study links later clinic visits to lower antihypertensive adherence

Estrogen-based hormone replacement therapy use is rising

Estrogen-based hormone replacement therapy use is rising

CDC publishes national COVID-19 analysis using Truveta Data in the MMWR

CDC publishes national COVID-19 analysis using Truveta Data

Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval – Truveta research report cover image.

Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval

Find more research

Featured in

Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Brand Name
Visit the newsroom

Follow us on LinkedIn to keep up with the latest from Truveta

Follow us

Interested in learning more?